Report #2833225

Received Mar 26, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 81 yrs
State: PA
Recovered: Not recovered
Vaccinated: Mar 10, 2025
Onset: Mar 15, 2025
Days to onset: 5
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	—

Symptoms (1)

Injection site erythema

Symptom narrative

redness at the injection site after receiving the first dose of Shingrix; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 81-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included blood cholesterol increased. Concomitant products included simvastatin. On 10-MAR-2025, the patient received the 1st dose of Shingrix. On 15-MAR-2025, 5 days after receiving Shingrix, the patient experienced injection site erythema (Verbatim: redness at the injection site after receiving the first dose of Shingrix). The outcome of the injection site erythema was resolving. It was unknown if the reporter considered the injection site erythema to be related to Shingrix. It was unknown if the company considered the injection site erythema to be related to Shingrix. Additional Information: GSK receipt date: 19-MAR-2025 Customer reported developing redness at the injection site after receiving the first dose of Shingrix. Vaccine was administered on 10th March 2025, redness developed on 15th March 2025.

Current illness

Blood cholesterol increased

Other medications

SIMVASTATIN